190 related articles for article (PubMed ID: 18050132)
1. Intravitreal ranibizumab in a patient with choroidal neovascularization secondary to multiple evanescent white dot syndrome.
Rouvas AA; Ladas ID; Papakostas TD; Moschos MM; Vergados I
Eur J Ophthalmol; 2007; 17(6):996-9. PubMed ID: 18050132
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal ranibizumab (Lucentis) for choroidal neovascularization associated with Stargardt's disease.
Querques G; Bocco MC; Soubrane G; Souied EH
Graefes Arch Clin Exp Ophthalmol; 2008 Feb; 246(2):319-21. PubMed ID: 17934751
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal ranibizumab for choroidal neovascularization related to traumatic Bruch's membrane rupture.
Liang F; Puche N; Soubrane G; Souied EH
Graefes Arch Clin Exp Ophthalmol; 2009 Sep; 247(9):1285-8. PubMed ID: 19468741
[TBL] [Abstract][Full Text] [Related]
4. Choroidal Neovascularization Associated with Multiple Evanescent White Dot Syndrome Treated with Intravitreal Ranibizumab.
Battaglia Parodi M; Iacono P; Zucchiatti I; Bandello F
Ocul Immunol Inflamm; 2018; 26(4):608-611. PubMed ID: 27892746
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal ranibizumab for choroidal neovascularization in a patient with angioid streaks and multiple evanescent white dots.
Pece A; Allegrini D; Kontadakis S; Querques G; Rossetti L
BMC Ophthalmol; 2016 Jul; 16():122. PubMed ID: 27457484
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal ranibizumab in the treatment of choroidal neovascularization associated with idiopathic central serous chorioretinopathy.
Konstantinidis L; Mantel I; Zografos L; Ambresin A
Eur J Ophthalmol; 2010; 20(5):955-8. PubMed ID: 20306440
[TBL] [Abstract][Full Text] [Related]
7. Ranibizumab treatment for choroidal neovascularization secondary to causes other than age-related macular degeneration with good baseline visual acuity.
Erol MK; Ozdemir O; Coban DT; Ceran BB; Bulut M
Semin Ophthalmol; 2014 Mar; 29(2):108-13. PubMed ID: 24409939
[TBL] [Abstract][Full Text] [Related]
8. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
Brown DM; Michels M; Kaiser PK; Heier JS; Sy JP; Ianchulev T;
Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
[TBL] [Abstract][Full Text] [Related]
9. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
Arias L; Ruiz-Moreno JM; Gómez-Ulla F; Fernández M; Montero J
Retina; 2009; 29(10):1444-9. PubMed ID: 19730163
[TBL] [Abstract][Full Text] [Related]
10. Ranibizumab therapy for choroidal neovascularization secondary to non-age-related macular degeneration causes.
Troutbeck R; Bunting R; van Heerdon A; Cain M; Guymer R
Clin Exp Ophthalmol; 2012; 40(1):67-72. PubMed ID: 22004186
[TBL] [Abstract][Full Text] [Related]
11. Treatment of choroidal neovascularization using intravitreal bevacizumab.
Pedersen R; Soliman W; Lund-Andersen H; Larsen M
Acta Ophthalmol Scand; 2007 Aug; 85(5):526-33. PubMed ID: 17511757
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
Rouvas A; Petrou P; Douvali M; Ntouraki A; Vergados I; Georgalas I; Markomichelakis N
Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab therapy for choroidal neovascularization secondary to age-related macular degeneration: 6-month results of an open-label uncontrolled clinical study.
Giansanti F; Virgili G; Bini A; Rapizzi E; Giacomelli G; Donati MC; Verdina T; Menchini U
Eur J Ophthalmol; 2007; 17(2):230-7. PubMed ID: 17415697
[TBL] [Abstract][Full Text] [Related]
15. Changes of choroidal neovascularization in indocyanine green angiography after intravitreal ranibizumab injection.
Lee JE; Kim HW; Lee SJ; Lee JE
Retina; 2015 May; 35(5):999-1006. PubMed ID: 25590857
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.
Furino C; Boscia F; Recchimurzo N; Besozzi G; Cardascia N; Sborgia L; Niro A; Sborgia C
Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335
[TBL] [Abstract][Full Text] [Related]
17. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.
Algvere PV; Steén B; Seregard S; Kvanta A
Acta Ophthalmol; 2008 Aug; 86(5):482-9. PubMed ID: 18162062
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab for peripapillary classic subretinal neovascularization.
Spandau UH; Jonas JB
Acta Ophthalmol Scand; 2007 May; 85(3):340-1. PubMed ID: 17488467
[No Abstract] [Full Text] [Related]
19. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.
Lazic R; Gabric N
Ophthalmology; 2007 Jun; 114(6):1179-85. PubMed ID: 17544776
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal ranibizumab (Lucentis) for choroidal neovascularization associated with vitelliform macular dystrophy.
Querques G; Bocco MC; Soubrane G; Souied EH
Acta Ophthalmol; 2008 Sep; 86(6):694-5. PubMed ID: 18752521
[No Abstract] [Full Text] [Related]
[Next] [New Search]
